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Edited by Judit Ova´diAbstract According to the chemical genetic approach, small
molecules that bind directly to proteins are used to analyze pro-
tein function, thereby enabling the elucidation of complex mech-
anisms in mammal cells. Thus, it is very important to identify the
molecular targets of compounds that induce a unique phenotype
in a target cell. Phoslactomycin A (PLMA) is known to be a po-
tent inhibitor of protein Ser/Thr phosphatase 2A (PP2A); how-
ever, the inhibitory mechanism of PP2A by PLMA has not yet
been elucidated. Here, we demonstrated that PLMA directly
binds to the PP2A catalytic subunit (PP2Ac) in cells by using
biotinylated PLMA, and the PLMA-binding site was identiﬁed
as the Cys-269 residue of PP2Ac. Moreover, we revealed that
the Cys-269 contributes to the potent inhibition of PP2Ac activ-
ity by PLMA. These results suggest that PLMA is a PP2A-
selective inhibitor and is therefore expected to be useful for
future investigation of PP2A function in cells.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Classic genetics based on the analyses of mutants has re-
vealed the molecular basis of diverse biological processes,
including cell division, diﬀerentiation, and apoptosis. This is
a powerful approach for identifying the speciﬁc genes respon-
sible for each biological process. However, it can be diﬃcult to
apply the genetic approach for use in mammals, because mam-
mals have redundant genes. To overcome this limitation of the
genetic approach, the chemical genetic approach has been
shown to be useful for elucidating the functions of complex
mammalian systems [1–5]. According to the chemical genetic
approach, small molecules, so-called bioprobes [1], are used
to directly alter protein function via binding to their protein
targets, and by either enhancing or inhibiting the function of
those targets. In particular, such compounds identiﬁed a targetAbbreviations: PLM, phoslactomycin; PLMA, phoslactomycin A; bio-
PLM, biotinylated PLMA; PP2A, protein Ser/Thr phosphatase 2A;
PP2Ac, catalytic subunit of PP2A; PP6, protein phosphatase 6; PP1,
protein phosphatase 1; IC, inhibitory concentration; OA, okadaic acid
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function of the protein in cells. To date, several bioactive
chemicals and their target proteins have been reported. One
such example would be pironetin, which binds to Lys-352 of
a-tubulin, inhibits tubulin assembly, and arrests cell cycle pro-
gression in M phase [6]. Another example reported to date is
amphidinolide H, which binds to Tyr-200 of actin subdomain
4 and stimulates the formation of small actin-patches, followed
by F-actin rearrangement into aggregates via the retraction of
actin ﬁbers [7].
Phoslactomycins (PLMs) A–F, biosynthesized using a
cyclohexanecarboxylic acid as the starter unit, were isolated
as antifungal antibiotics from Streptomyces sp. [8–11]. Previ-
ously, we reported that PLMs are potent protein Ser/Thr phos-
phatase 2A (PP2A) inhibitors in vitro [12]. Despite the
existence of numerous PP2A inhibitors such as okadaic acid
(OA) and fostriecin, the mechanisms of inhibition of PP2A
by these PP2A inhibitors remain obscure.
PP2A is involved in the control of a number of cellular func-
tions, including metabolism, transcription, translation, RNA
splicing, DNA replication, cell cycle progression, transforma-
tion, and apoptosis [13–19]. PP2A exists as a variety of trimers
consisting of A, B, and C subunits in mammalian cells. The C
subunit is the enzymatically active component, the A subunit is
a scaﬀolding component, and the B subunit acts as a targeting
module that directs the enzyme to various intracellular loca-
tions and also provides substrate speciﬁcity [20]. Various nat-
ural toxins such as microcystin, OA, and calyculin A were
bound to the catalytic subunit of both protein phosphatase 1
(PP1) and PP2A, and were shown to inhibit the activities of
both enzymes [21]. Moreover, the three-dimensional structures
of the PP1 catalytic subunit (PP1c) with microcystin [22], OA
[23], or calyculin A [24] have been reported. Because the three-
dimensional structure of the PP2A catalytic subunit (PP2Ac)
has not yet been resolved, only the classic genetic approach
has been used to create resistant mutants against its inhibitors
(e.g., OA [25], and fostriecin [26]), and the putative-binding site
has remained equivocal.
Here, we found that phoslactomycin A (PLMA) binds to
PP2Ac in cells. We also demonstrated by the systematic muta-
genesis of exogenous PP2Ac that the PLMA-binding site is
Cys-269 which is the important residue for inhibition of PP2Ac
activity by PLMA. Since the Cys-269 residue is located at the
predicted loop region between b12 and b13 of PP2Ac [24],
PLMA is expected to be a useful compound for investigation
of the cellular regulation of PP2A. Moreover, PLMA is also
expected to aid in the further clariﬁcation of the role of the
b12–b13 loop in PP2A function.blished by Elsevier B.V. All rights reserved.
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2.1. Synthesis of biotinylated phoslactomycin A
To a solution of PLMA (2.9 mg, 4.8 lmol) in anhydrous
N,N-dimethylformamide (100 lL), EZ-LinkTM NHS-LC-Biotin
(Pierce) (3.6 mg, 7.9 lmol, 1.6 eq.) and triethylamine (5 lL, 33 lmol,
6.9 eq.) were added at room temperature under an Ar atmosphere.
After 12 h, the reaction mixture was diluted with water (0.3 ml). Puri-
ﬁcation of the mixture on a small pipette column (Nakalai Cosmosil
140 C18-OPN, 0.8 g; 0ﬁ 100% aq. MeOH) gave a triethylamine salt
of biotinylated PLMA (bio-PLM) (4.7 mg, 94%) as a colorless oil.
The product (2.3 mg) was dissolved in water and loaded on a small
pipette column (Nakalai Cosmosil 140 C18-OPN, 0.8 g). The column
was washed by elution with water, 10 mM phosphate buﬀer (pH 7),
and water (10 ml each). Elution with MeOH (10 ml) aﬀorded bio-
PLM (2.0 mg) as a colorless oil.
The NMR spectrum was measured on a JEOL JNM-AL400 spec-
trometer. The following mass and MS/MS spectra were obtained on
a Perkin–Elmer SCIEX API 2000 pneumatically assisted electrospray
triplequadrapole mass spectrometer. Bio-PLM: 1H NMR (400 MHz,
CD3OD, 3.30) d 7.08 (1H, dd, J = 5.2, 9.8 Hz), 6.32 (1H, t,
J = 10.2 Hz), 6.24 (1H, t, J = 10. 2 Hz), 6.07 (1H, dd, J = 6.8,
15.6 Hz), 6.01 (1H, dd, J = 1.2, 9.8 Hz), 5.86 (1H, dd, J = 1.2,
15.6 Hz), 5.45 (1H, t, J = 10.2 Hz), 5.28 (1H, t, J = 10.2 Hz), 5.08
(1H, brt, J = 6.8 Hz), 5.01 (1H, dt, J = 4.0, 8.4 Hz), 4.70 (1H, tt,
J = 11.2, 4.0 Hz), 4.48 (1H, dd, J = 4.4, 8.0 Hz), 4.30 (1H, dd,
J = 4.8, 8.0 Hz), 4.21 (1H, dt, J = 4.0, 10.8 Hz), 3.34 (1H, m), 3.20
(2H, m), 3.15 (2H, dt, J = 2.0, 6.8 Hz), 2.92 (1H, dd, J = 4.8,
12.8 Hz), 2.70 (1H, brd, J = 12.8 Hz), 2.62 (1H, brd, J = 10.2 Hz),
2.52 (1H, m), 2.49 (1H, sep, J = 7.2 Hz), 1.0–2.21 (29H, m), 1.12
(6H, d, J = 7.2 Hz), 0.95 (3H, t, J = 7.6 Hz); MS (ESI) m/z 937.4
[M  H], 919.4 [M  H2O  H]; MS/MS (ESI) m/z 97.0 [H2PO4],
79.0 [PO3]
.2.2. Cell culture and transfection
HT1080 cells and HEK293 cells were cultured in Dulbeccos modi-
ﬁed Eagles medium supplemented with 10% fetal bovine serum in a
humidiﬁed atmosphere containing 5% CO2. Human PP2Aca, PP2Acb,
protein phosphatase 6 (PP6), and PP1 catalytic a isoform (PP1ca) were
subcloned into a pcDNA3.1/MycHis(+) vector (Invitrogen). We
substituted certain cysteine residues in PP2Aca with serine residues
by PCR site-directed mutagenesis using the overlap extension tech-
nique. Myc-tagged phosphatase-expressing cells were created by trans-
fecting the plasmids into exponentially growing HEK293 cells using
Eﬀectene transfection reagent (Qiagen).2.3. Western blot analysis
The cells were lysed in Lysis buﬀer (50 mM Tris–HCl, 150 mM
NaCl, 1 mM EDTA, 2.5 mM EGTA, 0.1% NP-40, 0.1 mM PMSF,
10 ng/ml aprotinin, and 10 ng/ml leupeptin [pH 7.5]) at 4 C. To detect
the cellular expression level of co-precipitated proteins with streptavi-
din–agarose (Calbiochem), the proteins were electrophoresed on SDS–
polyacrylamide gel, and immunoblotted with anti-Myc antibody
(9E10, BAbCO), anti-a-tubulin antibody (DM 1A, Sigma), anti-
PP2Ac antibody (rabbit polyclonal, Calbiochem), or anti-PP2A A sub-
unit (PP2Aa) antibody (rabbit polyclonal, Upstate Biotechnology).
2.4. In vitro protein phosphatase assay
PP2A from human red blood cells was purchased from Upstate Bio-
technology. OA was obtained from Calbiochem. In vitro phosphatase
assays were carried out at 30 C for 30 min using 0.01 unit/ll of the en-
zyme and 150 lM of phosphopeptide (K-R-pT-I-R-R; synthesized by
Sigma) in 100 ll of assay buﬀer (20 mM HEPES, 0.5 mM MgCl2,
and 10 mM NaCl [pH 7.5]). One hundred microliters of malachite
green reagent (0.034% malachite green, 4.2% ammonium molybdate,
and 0.01% Tween 20 in 1 N HCl aqueous solution) was added to the
reactant. The mixture was allowed to stand for 15 min at room temper-
ature, and absorbance was measured at 600 nm. The absorbance value
of the blank was subtracted from all of the results. The blank con-
tained the assay buﬀer and the malachite green reagent. The percentage
inhibition was calculated by the following equation: % inhibi-
tion = 100  (compound-contained experiment)/(vehicle-treated exper-
iment) · 100.2.5. Phoslactomycin-binding assay
To determine the level of PLM-binding proteins, HT1080 cells or
HEK293 cells were incubated with 2.5 lM of bio-PLM or biotin for
30 min. After the cells had been lysed with 100 ll of the Lysis buﬀer
(see above), the supernatants were prepared by centrifugation. Twenty
microliters of streptavidin–agarose were added to the lysates prepared
from cells treated with bio-PLM or biotin, and the mixtures were ro-
tated for 30 min at 4 C. The bound proteins were washed thoroughly
and boiled in 20 ll of SDS sample buﬀer (42 mM Tris–HCl, 10% glyc-
erol, 2.3% SDS, 5% 2-mercaptoethanol, and 0.002% bromophenol blue
[pH 6.8]). Each sample was subjected to SDS–PAGE (10% gel), and
the proteins were transferred to a poly(vinylidene ﬂuoride) membrane.
The transferred proteins bound to bio-PLM were subjected to immu-
noblotting using horseradish peroxidase-conjugated NeutrAvidin
(Piece), anti-PP2Ac, or anti-PP2Aa. The protein bands were visualized
using SuperSignal Substrate (Pierce).2.6. Partial puriﬁcation of PP2Ac proteins and measurement of
phosphatase activity
HEK293T cells were cultured in RPMI 1640 medium supplemented
with 10% fetal bovine serum in humidiﬁed atmosphere containing 5%
CO2. The cells transfected with MycHis-tagged wild-type or mutant
PP2Ac constructs, or empty vector. After 24 h, cells were lysed with
the Lysis buﬀer, and supernatants were obtained after centrifugation.
The pull-down fractions were collected with 10 ll of Ni–NTA Agarose
(QIAGEN), washed by centrifugation, and suspended in phosphatase
assay buﬀer (20 mM imidazole, 50 mM NaCl, 1 mM MgCl2, 1 mM
dithiothreitol, 10% glycerol, and 0.1 mg/ml bovine serum albumin
[pH 7.5]). The pull-down fractions were used for phosphatase assay
as described before and for immunoblotting with anti-Myc antibody
to show the amount of PP2Ac-MycHis protein in the assay.3. Results
3.1. Inhibition of PP2A activity by phoslactomycin and its
biotinylated analog in vitro
To identify the PLM-binding proteins, we synthesized a
PLM analog possessing a tethered biotin moiety (Fig. 1A).
The ability of PLMA and bio-PLM to inhibit human PP2A
in vitro was examined (Fig. 1B). The 50% inhibitory concen-
tration (IC50) of OA, PLMA, bio-PLM, and biotin were
0.001, 30, 1, and >100 lM, respectively. PLMA, with an amino
group, was found to be relatively weak in terms of PP2A inhib-
itory activity, which suggested that the amino group of PLMA
interfered with its phosphate group, which is thought to be
essential to PLMA for exerting PP2A inhibitory activity [27].
Thus, we decided that bio-PLM could be used for searching
for PLMA-binding protein(s).3.2. Phoslactomycin binds to the PP2A catalytic subunit in
intact cells
We next examined whether or not bio-PLM modiﬁes cellular
protein(s) in cells. Human ﬁbrosarcoma HT1080 cells were
incubated with 2.5 lM bio-PLM or biotin for 30 min. After
washing the cells, they were lysed, and the biotin-containing
complexes were isolated by the use of streptavidin-conjugated
agarose beads. The biotin- or bio-PLM-bound proteins were
analyzed by SDS–PAGE followed by silver staining or Wes-
tern blotting. The silver stain analysis revealed that certain
proteins were co-precipitated with the streptavidin-beads in
both biotin-treated cells and bio-PLM-treated cells; this sam-
ple was found to contain ﬁve additional bands (Fig. 2A, arrow-
heads; 120, 65, and three 36 kDa bands). Detection of
biotinylated protein using NeutrAvidin-HRP also demon-
strated that the sample from bio-PLM-treated cells was found
Fig. 1. Structures of PLMs and their PP2A inhibitory activity. (A)
Chemical structures of PLM-A, and bio-PLM. (B) Inhibition of PP2A
activity in vitro by PP2A inhibitors. PLMA (open circle), bio-PLM
(ﬁlled diamond), OA (open diamond), or biotin (ﬁlled circle).
Fig. 2. Identiﬁcation of PP2Ac as a bio-PLM-binding protein.
HT1080 cells were incubated with 2.5 lM biotin or 2.5 lM bio-PLM
for 30 min. After cell lysis, the proteins bound to bio-PLM or biotin
were precipitated by using immobilized streptavidin and were analyzed
by SDS–PAGE, followed by silver staining (A). The proteins subjected
to SDS–PAGE were transferred to membranes, and were stained with
horseradish peroxidase-conjugated avidin (B) or were immunoblotted
with two rabbit polyclonal antibodies raised against PP2Ac and
PP2Aa (C).
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biotin-treated cells (Fig. 2B). These data strongly suggested
that bio-PLM directly and covalently binds to 36 kDa pro-
teins, because the interaction was stable in the presence of
SDS and 2-mercaptoethanol, even after heat denaturation.
Since the PLMs possessed the ability to inhibit PP2A, we con-
ducted an investigation to determine whether or not the
36 kDa proteins were PP2Ac. As shown in Fig. 2C, it was re-
vealed by Western blotting using anti-PP2Ac antibody that
bio-PLM binds to PP2Ac in these cells. Thus, it appeared pos-
sible that the multiple 36 kDa bands were other catalytic sub-
units of the PP2A family proteins (e.g., PP2Aca/b, PP4, and
PP6). We conﬁrmed by Western blotting using anti-PP2Aa
antibody that 65 kDa was PP2Aa in the bio-PLM-treated sam-
ple (Fig. 2C). However, the identity of the 120 kDa protein is
still unknown (Fig. 2A, arrowhead).
Next, we performed a competition analysis using these cells.
The binding of bio-PLM to PP2Ac was rendered competitive
by the addition of PLMA or OA in a dose-dependent manner,
and the binding was completely blocked when 250 lM of
PLMA or 2.5 lM of OA was added to the culture medium
1 h before the addition of bio-PLM (Fig. 3). Similar results
were obtained by another PLM analog (data not shown).
These results suggest that PLM speciﬁcally binds to the
36 kDa cellular proteins such as PP2Ac, and that the binding
site of PLMA on PP2Ac might be identical to that of OA.
3.3. Phoslactomycin binds to Cys-269 of the PP2A catalytic
subunit
To identify the PLMA-binding site on PP2Ac in these cells, a
binding assay was carried out using diﬀerent C-terminal-deletedFig. 3. Competition analysis of bio-PLM-binding proteins. HT1080
cells were preincubated with PLMA (lanes 3–5 [2.5, 25, and 250 lM,
respectively]), or OA (lanes 6–8 [0.025, 0.25, and 2.5 lM, respectively])
or without competitor (lanes 1 and 2). After incubation for 1 h, the
cells were treated with bio-PLM or biotin, and were then incubated for
an additional 30 min, after which the cells were lysed, and the proteins
bound to bio-PLM were isolated by using streptavidin beads. The
beads were washed and analyzed by 10% SDS–PAGE followed by
Western blotting using avidin-HRP or anti-PP2Ac antibody.
2466 T. Teruya et al. / FEBS Letters 579 (2005) 2463–2468human PP2Acamutants (Fig. 4A). The mutants were expressed
inHEK293 cells, andwere tested in terms of the ability to bind to
bio-PLM. As shown in Fig. 4B, full-length PP2Aca (1–309), but
not the truncated mutants PP2Aca (1–261) and PP2Aca (1–
208), was precipitated with bio-PLM by the streptavidin-beads.
Thus, it appears likely that bio-PLM binds to the C-terminal re-
gion (262–309) of human PP2Aca.
PLMA has an electrophilic structure in its a,b-unsaturated
d-lactone, which is potentially reactive with biological nucleo-
philes such as the sulfhydryl of the cysteine residue. Since the
sulfhydryl group of a cysteine residue is expected to be the
binding site of PLMA, we used serine scanning for cysteine
to determine the PLMA-binding site. All 10 cysteine residues
of human PP2Aca (Fig. 4A) were changed to serine by PCR
mutagenesis. As shown in Fig. 4C, one of the mutants,
C269S, failed to precipitate with bio-PLM, whereas the other
mutants precipitated with bio-PLM. These results strongly
suggest that PLMA binds to Cys-269 of PP2Aca.Fig. 4. Determination of PP2A-binding site targeted by PLMA. (A)
Schematic diagram of Myc-tagged human PP2Ac used in this study.
Closed box indicates Myc-tag. (B) and (C) HEK293 cells were
transfected with equal amounts of empty vector or Myc-tagged PP2Ac
expression vectors (wild-type, truncated, or substituted mutants). After
24 h, bio-PLM (2.5 lM) was added to the culture medium for 30 min.
After incubation, the cells were lysed, and the proteins bound to bio-
PLM were precipitated by using streptavidin beads. The PP2Ac–bio-
PLM complex was detected by immunoblotting with anti-Myc
antibody. Tubulin was detected as an internal control. (B) C-
terminal-truncated mutants of PP2Ac were used. (C) Mutants were
used in which all cysteine residues in PP2Aca were individually
changed to serine.3.4. The PP2Aca C269S substitution confers phoslactomycin
resistance in vitro
To investigate the role of Cys-269 for PLMA inhibition of
PP2Ac activity, the PP2Aca wild-type, C269S, and C251S pro-
teins were partially puriﬁed from HEK293T cells. A similar
amount and total activity of enzyme was recovered from cells
expressing the wild-type or substituted forms, and each enzyme
displayed a similar rate of phosphopeptide substrate hydrolysis
in vitro (Fig. 5B). PLMA inhibited wild-type PP2Aca activity
in a dose-dependent manner. However, the C269S substitution
caused a strikingly decrease in the sensitivity of PP2Aca to
PLMA (50-fold increase in IC50) (Fig. 5C). A C251S mutant
can be bound to PLMA (Fig. 4C), and was used as a control.
PLMA inhibited the activity of PP2Aca C251S as same as that
of wild-type (Fig. 5C). Therefore, it is suggested that theFig. 5. Role of Cys-269 residue for inhibition of PP2Ac activity by
PLMA in vitro. (A) Western blot analysis of partially puriﬁed PP2Ac
proteins. A plasmid encoding the MycHis-tagged wild-type or substi-
tuted forms of PP2Aca, or the empty vector was introduced into
HEK293T cells. The expression levels of MycHis-tagged PP2Ac in the
total cell extracts and pull-down complexes were detected by Western
blot analysis with anti-Myc antibody. (B) Protein phosphatase activity
of partially puriﬁed PP2Ac. A plasmid encoding the MycHis-tagged
wild-type or substituted forms of PP2Aca, or the empty vector was
introduced into HEK293T cells. Phosphatase activity was assayed
from the pull-down fractions as described under Section 2. (C) Protein
phosphatase assays in vitro. The PP2Ac wild-type, C269S, and C251S
mutants were partially puriﬁed from HEK293T cells and assayed for
phosphatase activity in the absence or presence of PLMA. Data are
expressed as percentage of control activity in the absence of PLMA.
Wild-type (ﬁlled circle), C269S (open circle), or C251S (open triangle).
Mean values (±S.D.) are from three independent experiments.
Fig. 6. PLM targets the catalytic subunit of PP2A family proteins. (A)
The C-terminal residues of human PP1ca, PP2Aca, PP2Acb, and PP6
were aligned. The SAPNY motif in each sequence is underlined. (B):
HEK293 cells were transfected with empty vector or vectors encoding
Myc-tagged PP2Aca, PP2Acb, PP6, or PP1ca. After 24 h, bio-PLM
(2.5 lM) was added to the culture medium for 30 min. Bio-PLM
bound to phosphatases was collected with streptavidin beads. The bio-
PLM–phosphatase complex was detected by immunoblotting with
anti-Myc antibody.
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activity by PLMA.
3.5. Phoslactomycin binds to catalytic subunit of PP2A family
proteins
Amino acid sequence alignment (Fig. 6A) revealed that
PP2Aca, PP2Acb, and PP6 possess a cysteine residue at the
same location, i.e., at Cys-269, Cys-269, and Cys-265, respec-
tively; however, this residue is not contained in the sequence
of PP1ca. Thus, we then turned our attention to an examina-
tion of whether or not bio-PLM binds to phosphatases in these
cells. The results are shown in Fig. 5B. Bio-PLM was able to
bind to certain members of the PP2A family of proteins
(PP2Aa, PP2Ab, and PP6) but not to PP1ca. These data sup-
port the conclusion that Cys-269 of PP2Ac is the binding site
of PLMA in these cells.4. Discussion
Amutation can speciﬁcally alter the function of a single gene
within a complex genome. Because mutations can be made in
any gene, mutations are generally applicable and can be used
to study many biological processes. The use of exogenous li-
gands (e.g., small molecule compounds) as part of the chemical
genetic approach in place of mutations requires that such li-
gands have speciﬁc targets. Thus, the identiﬁcation of the tar-
get protein and its binding site is a very important step in
chemical genetics.
Amutation at theC269G residue of PP2Acwas identiﬁed dur-
ing a screen for conferring OA-resistance in CHO-K1 cells [25].
Furthermore, itwas also reported in a studyusing randommuta-genesis screening in yeast that PP2Ac mutants such as C269S,
Y267G, andG270Dwere less sensitive than wild-type to fostrie-
cin which is structurally similar to PLMA [26]. Thus, it has been
suggested that the loop domain between b12 and b13 (Fig. 6A) is
a critical region for the inhibition of PP2A activity by PP2A
inhibitors. In this report, we demonstrated that PLMA directly
binds to PP2Ac in cells and that the Cys-269 residue of PP2Ac is
the binding site of PLMA (Figs. 2 and 4). This is the ﬁrst report
to describe a direct interaction between PP2Ac and its inhibitor.
In this study, in order to search for a molecular target of
PLMA, we synthesized a biotinylated analog as a molecular
probe, and identiﬁed PP2Ac as a PLMA-binding protein.
The bio-PLM binds to the catalytic subunit of PP2A family
proteins (Fig. 2). The proteins were precipitated with bio-
PLM in Fig. 2A and B. All the proteins precipitated with
bio-PLM were observed by silver staining (Fig. 2A). On the
other hand, the proteins directly bound with bio-PLM were
observed by avidin linked horseradish peroxidase detection
(Fig. 2B). PP2Aa (65 kDa) and unidentiﬁed 120 kDa protein
were detected in Fig. 2A but not in Fig. 2B. Thus, we speculate
that the 120 kDa protein may be a protein that associates with
one of the PP2A isoforms such as a substrate or regulator.
However, the identity of the 120 kDa protein has not been
determined. Although PLMA has an electrophilic structure
in its a,b-unsaturated d-lactone, which is potentially reactive
with biological nucleophiles, a pull-down assay with streptavi-
din beads indicated that bio-PLM speciﬁcally binds to the
PP2A family proteins (Fig. 2). To date, some bioactive com-
pounds containing a,b-unsaturated lactone have been reported
to bind to proteins by Michael addition, a reaction that is
likely to be non-speciﬁc to biological nucleophiles such as cys-
teine residues; however, it has been shown that the binding of
some compounds such as leptomycin B [28], and pironetin [6]
to targeted proteins proceeds in a site and/or protein-speciﬁc
manner. As for PP2A inhibitors, although it is speculated that
fostriecin covalently binds to PP2Ac through the unsatulated
lactone, the direct evidence has not yet been reported. On
the other hand, OA does not include functional groups which
could covalently bind to proteins, thus, OA might bind to
PP2Ac with several hydrogen and/or hydrophobic bonds with-
in the active site. Here, we identiﬁed that the PLMA-binding
site is Cys-269 of PP2Ac by the systematic mutagenesis of
exogenous PP2Ac (Fig. 4). Moreover, it was demonstrated
that the Cys-269 contributes to the inhibition of phosphatase
activity by PLMA, because a mutant, C269S, increased the
IC50 by at least 50-fold compared with wild-type (Fig. 5C).
Thus, the high speciﬁcity of PLMA bound to and inhibition
of PP2Ac is thought to be due to structural elements, in addi-
tion to the lactone moiety. Further study will still be necessary
in order to clarify the binding mechanisms of PLMA to
PP2Ac. Interestingly, the binding of PLMA to PP2Ac was
inhibited by the addition of OA (Fig. 3), thus suggesting that
the binding site of PP2Ac to OA might be identical site to
PLMA. These results were supported by previous reports dem-
onstrating that C269G and C269S substitutions increased the
IC50 of PP2Aca for OA [25] and fostriecin [26].
Novel Ser/Thr phosphatases such as PP4, PP5, PP6, and PP7
have also been identiﬁed using a molecular cloning strategy
and a biochemical approach [29]. When compared to these
phosphatases, the PP4 and PP6 catalytic subunits were found
to be very similar to the PP2A family members, and they have
60–65% amino acid sequence identity with PP2Ac [30]. We
2468 T. Teruya et al. / FEBS Letters 579 (2005) 2463–2468predicted that PLMA would be able to bind to the PP2A fam-
ily members, because the residue corresponding to Cys-269 in
PP2Ac is conserved among them (Fig. 6A). Indeed, PP2Aca,
PP2Acb, and PP6 were precipitated with bio-PLM by the
use of streptavidin beads; however, PP1ca, which is not a
PP2A family member, was not precipitated at all (Fig. 6B).
Therefore, we concluded that the Cys-269 residue of PP2Ac
is indeed a PLMA-binding site. This paper is the ﬁrst report
to reveal a direct interaction between PP2Ac Cys-269 and
PP2A inhibitor in intact cells. An understanding of the molec-
ular interactions occurring between PLMA and PP2Ac may
help in the design of novel drugs with increased eﬃcacy and
low general toxicity.
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